In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses one criticism made by Eli Lilly (NYSE:LLY) CEO John Lechleiter of a problem facing big pharmaceutical companies in Europe: Drugs are too cheap. He specifically focuses on how differences in European health-care systems vs. those in the United States mean a lot of pressure to lower prices on pharmaceuticals in Europe, which is damaging to the industry.